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ONCOL G
For Cancer Patients,
Home May Be Their Hospital
Physicians at M. D. Anderson Cancer Center like John
Kavanagh, M.D., are referring patients to home health
care agencies for many treatments that used to be administered on an inpatient basis. "Life-particularly for cancer
patients-is very valuable, so hospital days are wasted days.
If you can reduce their stay, that's a service to them," said
Kavanagh, chief of the Section of Gynecologic Medical
Oncology.
Kavanagh said he became interested in home health
care when he noticed that many of the patients he saw
on rounds did not require intensive nursing care. Knowing
that patient education had become so specialized that
nurses could evaluate patients and provide them with safe
home-care standards, Kavanagh began to realize that
"some patients were wasting their time in the hospital."
Currently, providing hospice care and administering
chemotherapy, pain control therapy, parenteral nutrition,
and intravenous antibiotic therapy to patients at home is a
$3 billion/year industry that may reach $10 billion/year by
the year 2010, according to Edward Rubenstein, M.D.
Rubenstein, chief of General
Internal Medicine for the Department of Medical Specialties,
is director of the Ambulatory ·
Treatment Center, where outpatient chemotherapy is administered and patients with medical emergencies are treated.
He, like Kavanagh, believes
that more patients can be referred to home health care
Edward Rubenstein
agencies. "Patients recuperate
best when they're at home, not in the hospital, Rubenstein
said. For some, home care means a combination of home
and hospital therapy. For example, one patient admitted

for a liver chemoembolization required hospitalization.
"But after she was discharged," Rubenstein said, "some of
her blood cultures came back positive. She was called
into the outpatient area; because she looked well, she was
treated at home with intravenous antibiotics administered
via infusion pumps. She subsequently was readmitted to
the hospital for drainage of a liver abscess and then was
discharged for more home care," Rubenstein summarized.

"What happens now is that some patients are routed directly to home care without eing a itte .
er patients are discharged from the hospital early to finish up
treatment at home or referred for nutritional support at
home. Patients on 14 days of antibiotics may be admitted
for the first 7 days to make sure they're stable and finish up
the last half of their therapy at home. Chemotherapy also
can easily be given at home."
Deciding where patients are treated "depends upon what
the patients' resources are, how comfortable they are, and
what kind of support systems they have in the home environment," Rubenstein said. In fact, selecting patients
who will do well in home care is critical to making home
continued on page 2
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care work. "The key to choosing patients is what happens
in the clinic, in the outpatient arena," Rubenstein said. "If
you make the wrong decision in the outpatient area, the
patient who should be admitted is discharged only to
return, and the patient who is admitted to the hospital but
doesn't need to be does not get the benefits of the home
care system. People in health care must understand that
the model for home care really begins in the outpatient
area, in selective utilization of diagnostic evaluations and
patient assessment."

new catastrophic coverage rules.
An accompanying technology boom has given home
care agencies the ability to compete on more than a price
basis. Particularly in the past five years, advances in pump,
data facsimile, and paging technology, along with a larger
array of antibiotics and devices such as portable x-ray
machines, have "made it seem very reasonable that much ·
of what you do in the hospital could be done at homewth the same or greater efficiency," according to Kavanagh.
Candidates for home chemotherapy must be ambulatory
and free of disease symptoms, such as nausea, that would
intensify therapy side effects, Kavanagh said . Usually,
patients also need someone (generally a relative or friend)
to assist in their care. "In most home care situations, except for the extremely ambulatory patients, somebody has
to assist in the care, which involves a multitude of tasks."

Home Care Reduces
Patient Anxiety
Home care is usually less
expensive, but more important it also has the potential
to reduce patient anxiety.
"Patients who have cancer
have a very delicate emotional
homeostasis," Kavanagh said.
"They are upset very easily;
John Kavanagh
they are constantly coping with
the disease-while trying to
maintain some degree of contentment and satisfaction in
their lives. Many patients do not want to be treated in
an outpatient area or be admitted to the hospital. While
M. D. Anderson segregates patients according to disease
and general strength, outpatient areas still provoke
anxiety in most patients. Typically, there are both very
ill and relatively well patients in these areas, with a wide
range of pain and discomfort."
Also, some patients do not feel they can afford the time
away from work that even outpatient visits require. "Many
patients would like to protect their employment status
and are, in a sense, healthy enough to have active lives.
They would like a minimum of infringement on their
normal lives," Kavanagh said.

Patients Referred to Approved Agencies
Patients or their insurance companies contract with
home care agencies, and M. D . Anderson physicians and
discharge-planning nurses work from a list of approve~
agencies in referring patients to home care . "The physician should have a major role in the choice because he or
she is ultimately responsible for the care of that patient.
Furthermore, the physician has to have a regular, reliable
line of communication with agency personnel. Because
the home environment is not problem free , medical and
nursing decisions have to be made on a continuous
basis," Kavanagh said.

Cost Containment the Impetus for Home Care
Kavanagh and Rubenstein agree that the national push
for cost containment, largely driven by Medicare and
private insurance companies, has doubtless powered the
movement toward home care. In 1986, Kavanagh and
co-investigators found, for example, that a cisplatin regimen administered at home for women with gynecologic
cancers was just as effective as and somewhat less expensive
than cisplatin therapy in the hospital.
Other studies have shown a 50 to 70% cost savings for
home parenteral nutrition, cost savings and comparable
efficiency for home antibiotic infusion, and hospice care
quality comparable to that of hospital care. Medicare will
cover more home care services beginning in 1990 under its

Money is not necessarily an obstacle to home care, as
a number of agencies take a proportion of indigent
patients. Rubenstein added that the 1990 expansion of
Medicare/Medicaid home care coverage will allow many
more indigent patients to receive therapy at home.
How often physicians at M. D. Anderson see their home
care patients in the clinic depends on the therapy the
patients are receiving and how ill they are. For instance, a
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patient on a routine antibiotic who is discharged feeling
well may be seen every two or three days. These patients
learn to hang the antibiotic bags on their IV poles and to
heparin flush their lines, or they may be on an ambulatory pump that delivers the antibiotics on a preprogrammed schedule. Sicker patients or those in pain may
be seen daily at first, whereas others may be seen once a
week or once a month. If possible, patients are dis·c harged
to their community physicians.
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might still be eligible for home care. For these patients,
"the hospice contribution is immense; it is the exception
rather than the rule that we have to keep people in the
hospital for the final phases of their illnesses," Kavanagh
said. "I always give them a choice. If they are comfortable
and the communication with the family is good, patients,
almost without exception, will want to be at home."
Unless they have a medically uncontrollable problem,
they can go home. "And as time goes on, we're able to
treat more of the previously uncontrollable problems at
home, including pain, vomiting, agitated states, and
seizure disorders."

More Home Care Research Is Necessary
Kavanagh encourages his colleagues not only to refer
more patients to home nursing care but also to conduct
home care research. His 1986 home chemotherapy study
was unique because it used cisplatin. "At the time, people
said it couldn't be used safely at home, so we were very
cautious about it. It turned out we needn't have." Other
innovative home chemotherapy studies are under way,
and more studies using available pump technology to
deliver medications f~r resistant pain are needed, he said.
"My patient population (women with cervical or recurrent
pelvic cancers, for the most part) has very difficult pain
problems . Since some are unable to take medications
orally, pump technology is very exciting." M. D.
Anderson's outpatients currently use the Baxter Travenol
Infusor balloon pump, the portable large-volume Pancreatec pump, the Baxter Auto-Syringe, and the Medfusion Infumed-300 pump for home therapy. About 400
patients a mon th now receive home chemotherapy.

Intermediate-care Units Should Be Developed

For those who cannot be placed under hospice care
because they do not have someone to assist in their care,
Kavanagh would like to see intermediate-care units
developed. "There are people who have no spouse, no
Liability May Impede Advances
family. Their friendships are limited, their religious ties are
Although innovation and caution necessarily go handweak. And so they have no one. One thing that has not
in-hand, Kavanagh worries that potential liability issues
really been developed is the concept of intermediatecould unduly impede technologic advancement. For incare units for predominantly self-reliant patients who
stance, questions about potential liability have been raised
nevertheless require very limited nursing care. Inpatient
about home blood transfusions, although no problems
hospice units are generally places of intense supportive
have occurred yet. Kavanagh wants to see a reasonable
care," he said.
partnership between law and medicine in new areas of
Kavanagh cautioned against too heavy a reliance on
medicine and health care delivery, with the emphasis on
traditional methods of treatment. "We shouldn't automadeveloping innovative home care techniques.
:tically dismiss the idea that something can be done a1t
_ _ S~o~me therapies are not given in patients' home_s_b_e_c_a_u_se_ __ _ home just because it never has been. It should be subthe therapies are too new. Experimental chemotherapy
jected to clinical research. As any technology develops in
for example, is only given in the hospital because "the
medicine, we should consider whether it has any homedrugs we're using are more unusual and the side effects
care applications. We should view home care from the
are more difficult to discern and deal with, particularly for
perspective of how we can make life more efficient and
the biologic compounds," Kavanagh said. Rubenstein
easier for the patient." ■
added that a definitive diagnosis is essential before home
care is considered. Surgery candidates and patients who
Physicians who desire additional information may write John Kavanagh,
M.D ., Department of Gynecology, Box 67, or Edward Rubenstein, M.D. ,
have chest pain, are severely short of breath, require
Department of Medical Specialties, Box 40, The University of Texas
intensive inpatient monitoring, or are otherwise unstable
M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,
are not home care candidates, Rubenstein said.
Texas 77030, or call (713) 792-2770 (Kavanagh) or (713) 792 -8645
Terminally ill patients, even those with intractable pain,
(Rubenstein).
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Newer Methods of Delivery
To Enhance GI Cancer Treatment
can't control the complications with medications, we \\ill
stop the chemotherapy first, and frequently the toxic
effects reverse enough so that the patient can maintain
his or her course of radiotherapy," Rich said.
Traditionally, 5-FU has been the chemotherapeutic
agent of choice for advanced adenocarcinoma of the GI
tract, achieving objective response rates of 8 to 20% when
administered in bolus-dose schedules. One obstacle to
improving these rates was the maximum tolerated dose.
Bolus-dose 5-FU must be limited to 15 m g/day admini-

When the medical breakthrough does not happen, the
only alternative is painstaking
research-progress in steps,
not leaps. It is a reality that
Tyvin Rich, M.D., Department
of Clinical Radiotherapy,
well understands. Rich and
his colleagues at the M. D.
Anderson Cancer Center have
Tyvin Rich
been studying new ways of
administering conventional chemoradiation treatments
for advanced local gastrointestinal ( GI) cancer,. These
treatments consist of various combinations of low-dose
continuous-infusion 5-fluorouracil ( 5-FU) and cisplatin,
external and intraoperative radiotherapy, and surgery. In
terms of patient survival rates, Rich acknowledged that
"we have yet to hit the home run, but in any research
home runs are few and far between."
Nevertheless, progress is being made. Because of reports
suggesting that these combined-modality approaches
improve tumor response and have acceptable levels of
toxicity, Rich believes that research "has come a step
forward in the treatment of advanced GI diseases."

stered for no more than three days. H igher bolus doses
result in unacceptable degrees of leukopenia and stomatitis
Continuous Infusion of 5-FU Allows
and sometimes death. With the advent of new portable
Higher Cumulative Doses
infusion pump technology, continµous infusion of 5-FU
For the past five years, the M. D. Anderson Cancer
began to be explored. Since 1981, various reports have
Center has been studying low-dose continuous-infusion
indicated that the cumulative dose of continuous-infusion
5-FU combined with conventionally fractionated external
5-FU can be three to four times higher than 5-FU adminiradiotherapy. The improvement in tumor response, local
stered in bolus-dose schedules.
control, and survival rates as yet can only be compared
The rationale for continuously infusing low doses of
with those for historic controls; consequently, Rich said
5-FU rests not only in the lower toxicity. Continuous
that "we will need to verify these results with appropriate
infusion also increases the drug's ability to induce tumor
randomized studies." What is certain, he added,_i_s_th
_ at_ _ __ _ responses. In vitro studies show "that tumor cell kill in- ~ th~e- side effects associated with a 5- FU dose given in bolus
creases as time of exposure to this chemotherapeutic
schedules ( 15 mg/kg/ day for three days) are different,
agent increases. Furthermore, if one looks at tumor cell
more easily managed, and sometimes less severe (hema kill when 5-FU is combined with radiotherapy, one can,
topoietic) when the drug is given continuously ( 300 mg/
again, further maximize tumor cell kill by giving the drug
m 2'/ day for 30 to 40 days). All patients can be treated as
over time periods that are at least equal to the cell cycle
outpatients, he added, since safe, practical, low-cost
(10 to 30 hours)," Rich said.
infusion pumps are now available.
"Our goal is for the patient to maintain a normal dietary
intake and GI bowel habit and to still be active. But the
Cancer Cells Are Vulnerable Only in
toxicities of the fractionated radiotherapy and low-dose
Certain Phases of Cycle
chemotherapy are cumulative, so usually by the fourth or
Most antimetabolites like 5-FU are phase-specific agents
fifth week, a maximum tolerated dose is achieved. If we
that "almost exclusively kill" cells that are dividing, Rich
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our objective bein·g to determine the maximum tolerated
dose of low-dose continuous-infusion cisplatin with preoperative radiotherapy. We're particularly interested in
cisplatin because it interacts, we believe, differently with
radiotherapy than do the ~ntimetabolites, and it also may
have an enhanced effect when combined with 5-FU."

said. "These drugs have a very short half-life. This, combined with the fact that in any given tumor only a very
small proportion of the cells may be in a susceptible
phase of the cell cycle, means that short bolus doses may
be less effective. Bathing the tumor in a low-dose continuous-infusion drug will ensure that, when the cell goes
into cycle, the drug will be there to affect it."
Rich said that this effect may be enhanced when radiation is administered with chemotherapy, since the radiation, in addition to killing cells, may also induce dormant
cells to proliferate, thus making them more vulnerable to
5-FU. "Notice that I said 'enhance,' not 'radiosensitize.'
We're not certain exactly how this interaction is occurring, so to use 'radiosensitize' would presum<; the drug
exclusively affects the tumor's response to radiation. From
a mechanistic point of view, the radiation may just as well
be altering the cell's metabolism, making the cell more
susceptible to the drug,_" he said.
Other chemoradiation research includes a multi-institution study directed by the Radiotherapy Treatment Group,
headquartered in Philadelphia. "This study focuses on
patients with rectal cancer who need adjuvant treatment.
We're trying to determine whether bolus-dose 5-FU or
continuous-dose 5-FU combined with pelvic radiotherapy
reduces the risk of pelvic disease recurrence. Two
hundred patients are entered in the study, and we hope
to have a total of 400 early in 1990."
Rich and his colleagues also plan to extend their 5-FU
and external- beam radiation studies by adding cisplatin to
the protocol. "We've completed a phase I study in patients with advanced primary or recurrent rectal cancer,

Intraoperative Radiotherapy Minimizes Normal
Tissue Complications
One objective of the continuous-infusion studies has
been to mitigate the toxic effects of ~hemotherapy. On
another front, Rich and his colleagues are examining how
radiotherapy administered during surgery can reduce
toxicity. "When using external-beam radiotherapy, there
comes a point at which the risk of severe toxic effects to
normal tissue is too great," Rich said. "Rather than ask the
patient to undergo that risk, we sometimes use intraoperative radiotherapy. We can consequently improve the therapeutic ratio by literally removing normal tissue from the
beam's path and precisely focusing the radiation on the
tumor itself during surgery."
Rich again stressed that intraoperative radiotherapy is
but one facet of the combined-modality approach that ·
includes resection of the tumor (when possible), as well
as chemotherapy and conventional radiotherapy. "Since
we appear to be achieving a greater amount of tumor
shrinkage with the combination of chemotherapy and radiotherapy, it was logical to bring the surgeon into the
equation to maximize the chance for local cure."
continued on page 7
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Schematic representation of combined-modality therapy for gastrointestinal cancer. Treatment consists of two phases. First phase, external radiotherapy (XRT) plus chemotherapy. Second phase, intraoperative XRT. Figure shows
treatment of patient with either pancreatic (unresectable) or rectal (resectoble) tumor. "90%" and "10%" indicate isodose lines.
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Neoadiuvant continued from page 8
reduced to between 20 and 30%. However, the major
problem with patients with stage III breast cancer is
distant metastases, which inevitably cause organ dysfunction and death.
By the early 1970s, it became clear that chemotherapy
had to play a role in treatment if metastases were to be
controlled, and consequently several centers initiated
combined-modality programs. Investigators at the National Cancer Institute of Italy in Milan gave four cycles
of combined neoadjuvant chemotherapy consisting of
doxorubicin and vincristine to patients with locally advanced breast cancer. ("Neoadjuvant chemotherapy" is
the name given to chemotherapy administered before
primary therapy, be it surgery or radiotherapy.) All
patients received radiation therapy, which was the only
local treatment, and were then randomly assigned to a
control group or a group that received adjuvant chemotherapy. Eighty-three percent of llO patients in the
control group were rendered disease free, with a threeyear survival rate of 50%, and the patients who received
adjuvant chemotherapy had an even better survival rate.

174 patients were rendered disease free by this combined-modality therapy, and their median survival was 66
months. The five-year overall survival rate of this group
was 55%, and at 10 years 30% was disease free.

Combined-modality Therapy Improves
Remission and Survival
Many other clinical trials of combined-modality treatment have been initiated over the last 15 years. Most of
them have a shorter follow-up than the studies mentioned
above. However, all of them have confirmed that neoadjuvant chemotherapy, followed by local treatment and
adjuvant chemotherapy, produces a high complete
remission rate and substantially improved three- and fiveyear survival rates compared with those historically
achieved with local therapies only. The Milan experience
and our own also demonstrate that many of these patients remain disease free without maintenance therapy
longer than 10 years and that recurrences beyond five
yea.r;s are exceptional. This information suggests that
some patients with locally advanced breast cancer derive
a major, long-term benefit from combined-modality
therapy.

Patients with Inflammatory Breast Cancer Demonstrate Most Improvement
The most dramatic benefit from combined-modality
therapy occurred in those patients who had inflammatory
breast carcinoma. Ninety-five percent of these patients
develop local recurrence, distant metastases, or both
within one year of local treatment, and almost all of them
die within two years of diagnosis. Since the introduction
of combined-modality therapies including neoadjuvant
chemotherapy, the prognosis of patients with inflammatory breast carcinoma-the majority of whom can be
rendered disease free-has improved dramatically. Many
recent publications report three-year survival rates of 25
to 80%. Our own experience shows five-year survival
rates of 34% for our first combined-modality protocol
(FAC-radiotherapy-FAC) and 55% for our second (FACsurgery-FAC-radiotherapy). The largest report published
by investigators from the Institut Gustave-Roussy in Paris
included 170 patients treated with combined-modality
therapy. A five-year survival rate of 66% was reported by
this group, a clear departure from historical experience.
Preoperative, or neoadjuvant, chemotherapy was developed simultaneously with standard postoperative adjuvant
chemotherapy. Both have theoretical advantages and
disadvantages. Because standard postoperative chemotherapy is administered after surgical resection has
reduced the tumor burden to a minimum, the physician

In a subsequent study, the same investigators demonstrated that, after neoadjuvant chemotherapy, either
radiation therapy alone or surgery alone produced
equivalent local control rates. The overall experience of
the Milan group has shown, however, that combinedmodality therapy, including neoadjuvant chemotherapy
followed by surgical resection and adjuvant chemotherapy, produced the best long-term local control and
overall survival rates.
In 1973 our group at The University of Texas M. D.
Anderson Cancer Center initiated a combined-modality
program with FAC chemotherapy (5-fluorouracil, adriamycin ( doxorubicin), cyclophosphamide) administered for
three cycles befor_e local treatment. Most patients were
then treated with a total mastectomy followed by radiation therapy and adjuvant chemotherapy; a few others
had achieved a marked reduction in tumor volume after
neoadjuvant chemotherapy and consequently received
radiation therapy as the only local modality, followed, in
turn, by adjuvant chemotherapy. Ninety-six percent of
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has the benefit of an accurate surgical pathological
staging for evaluation of prognosis.· The disadvantages of
postoperative adjuvant chemotherapy consist of delayed
initiation, since local therapies have to be completed first,
and the fact that, in the absence of any disease, adjuvant
chemotherapy is administered blindly, without any
practical way of monitoring results.

President, The University of Texas M. D. Anderson Cancer Center
Charles A. LeMaistre, M.D.

Vice President for Academic Affairs
James M. Bowen, Ph .D.

Associate Vice President for Academic Affairs
Robin R. Sandefur, Ph .D.
Director, Department of Scientific Publications

Ineffective Therapy Can Be Discontinued Early

Walter J. Pagel

Neoadjuvant chemotherapy, on the other hand, can be
started early, upon confirmation of the diagnosis of
malignant disease, and the primary tumor itself (or the
enlarged regional lymph nodes) serves as a signal lesion
for monitoring the effects of therapy. Thus, ineffective
therapy can be discontinued early, avoiding unnecessary
toxicity. In addition, patients who achieve a marked
reduction in tumor volume by neoadjuvant chemotherapy
may benefit from breast conservation therapy, as opposed
to radical local treatments. Finally, preclinical experiments
have suggested that shortly after surgical resection of the
primary tumor, there is a substantial growth spurt of
micrometastases, which is difficult to treat with postoperative chemotherapy. However, micrometastases possibly
can be abrogated by the administration of neoadjuvant
chemotherapy. Extensive experience with these combined-modality therapies has already taught us that
neither surgical nor radiotherapy-related complications
are increased. H owever, neoadjuvant chemotherapy, like
all treatment modalities, is less effective against a large
tumor burden; large tumors usually harbor many tumor
cells with inherent resistance to chemotherapy.
Many questions remain in relation to the proper place of
adjuvant versus neoadjuvant chemotherapy for primary
breast cancer. H owever, for patients with inoperable,
locally advanced breast cancer, it appears that neoadjuvant chemotherapy is the treatment of choice, and that
combined-modality treatments that include neoadjuvant
chemotherapy are not only palliative but also provide
long-term, disease-free survival for a substantial fraction
of these patients . For patients with operable stage III
breast cancer, it is uncertain if neoadjuvant chemotherapy
is superior to postoperative adjuvant therapy. However,
the one advantage of neoadjuvant chemotherapy is that it
may offer (by producing substantial reductions in tumor
burden) the possibility of breast conservation therapy for
50 to 70% of patients. The study of these two combinedmodality therapies will allow us to develop better treatment strategies for our patients within the next decade. ■

Editor

Contributing Editor

Kevin Flynn

Mary Markell

Currently, patients with advanced colorectal disease are
being treated using all modalities. Preoperative therapy
consists of 5-FU and cisplatin infusion plus external radiotherapy. Therapy ceases for several weeks to allow maximum tumor regression. The tumor is then resected, and
an intraoperative radiation boost is given.
"We're very excited about the preliminary results," Rich
said. "Patients get through the preoperative treatment
well, and at surgery we're finding that the tumor has been
reduced. But we're still in a pilot phase."
For patients with advanced GI cancer, the home run
has yet to be hit; the bottom line in any cancer research
is patient survival. Rich acknowledged the task is difficult.
The therapeutic ratio for these patients needs improvement, survival averaging less than 50% at five years.
Rich hopes that improved tumor response due to newer
methods of drug and radiotherapy delivery will translate
into improved patient survival, but a definitive conclusion
awaits the results of prospective, randomized studies. ■

Physicians who desire additional information may write Gabriel N.
Hortobagyi, M.D., Department of Medical Oncology, Box 78, The
University of Texas M . D . Anderson Cancer Center, 1515 Holcombe
Boulevard, Houston, Texas, or call (713) 792-2817.

Physicians who desire additional information may write Tyvin A. Rich,
M .D ., Department of Clinical Radiotherapy, Box 97, The University of
Texas M. D . Anderson Cancer Center, 1515 H olcombe Boulevard,
Houston, Texas 77030, or call (713 ) 792 -2972.
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Neoadiuvant Chemotherapy for
Patients with Stage Ill Breast Cancer
by Gabriel N. Hortobagyi, M.D.

These responses were an improvement over p~evious
therapies that consisted only of local therapy-surgery,
radiation, or both. Patients who underwent these therapies achieved five-year survival rates ranging from 30 to
40% for operable stage III breast cancer and 10 to 20%
for inoperable disease. Because of high, early mortality,
few data on 10-year survival rates exist, but the accepted
estimates are approximately 20 to 25% for patients with
operable disease and less than 10% for those with inoperable disease, although an occasional report shows slightly
better results. When only one local therapy was given,
local control rates were poor, and depending on the
exact selection of patients, the lifetime local recurrence
rate varied from 30% to as high as 87%.

Chief, Breast Medical Oncology
Department of Medical Oncology

Many physicians once
considered stage III breast
cancer essentially incurable.
Consequently, curative
attempts were seldom initiated, and patients with locally
advanced breast cancer were
included in palliative treatment
programs. However, beginning two decades ago, it soon
Gabriel Hortobagyi
became apparent that the objective response rate to combination chemotherapy was
quite high, and many patients previously considered
inoperable had substantial reduction in the extent of
tumor, which often converted the primary tumor from
inoperable to operable.

Primary Obstacle Is Distant Metastases
Combined surgery and radiation therapy improved local
control rates, and local or regional recurrence rates were
continued on page 6
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